Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Riverwater Partners LLC

Riverwater Partners LLC grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 7.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,140 shares of the company’s stock after acquiring an additional 365 shares during the period. Riverwater Partners LLC’s holdings in Henry Schein were worth $356,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HSIC. Norges Bank purchased a new stake in Henry Schein during the fourth quarter worth $103,301,000. National Bank of Canada FI grew its stake in Henry Schein by 102.4% in the 4th quarter. National Bank of Canada FI now owns 1,084,511 shares of the company’s stock valued at $75,048,000 after acquiring an additional 548,561 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Henry Schein during the 4th quarter valued at about $34,720,000. ING Groep NV raised its position in Henry Schein by 34.1% during the fourth quarter. ING Groep NV now owns 1,163,087 shares of the company’s stock worth $80,486,000 after acquiring an additional 295,785 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new stake in shares of Henry Schein in the fourth quarter valued at about $12,179,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $65.47 on Friday. The company has a market cap of $8.13 billion, a P/E ratio of 26.94, a P/E/G ratio of 2.13 and a beta of 0.84. The firm’s 50 day moving average is $73.96 and its two-hundred day moving average is $72.57. Henry Schein, Inc. has a fifty-two week low of $63.00 and a fifty-two week high of $82.49. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the business posted $0.66 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insider Activity

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HSIC shares. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, February 26th. Barrington Research reissued an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Wells Fargo & Company began coverage on Henry Schein in a research note on Friday, February 14th. They set an “equal weight” rating and a $80.00 price objective on the stock. Jefferies Financial Group boosted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Finally, Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.